Slayback Pharma

Slayback Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.

Company Details

Employees
46
Founded
-
Address
301 Carnegie Center, Princeton,new Jersey 08540,united States
Phone
609-945-3443
Email
co****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Bachupally.
HQ
Princeton, New Jersey
Looking for a particular Slayback Pharma employee's phone or email?

Slayback Pharma Questions

News

Azurity Pharmaceuticals Acquires Slayback Pharma - PR Newswire

Azurity Pharmaceuticals Acquires Slayback Pharma PR Newswire

White & Case advises Azurity Pharmaceuticals, Inc. on acquisition of Slayback Pharma, LLC - White & Case LLP

White & Case advises Azurity Pharmaceuticals, Inc. on acquisition of Slayback Pharma, LLC White & Case LLP

Slayback Pharma appoints head of global R&D - ROI-NJ

Slayback Pharma appoints head of global R&D ROI-NJ

Slayback Pharma announces investment of $50 million by The Everstone Group - PR Newswire

Slayback Pharma announces investment of $50 million by The Everstone Group PR Newswire

Slayback Pharma in Hyderabad by Studio Mohenjodaro - ArchitectureLive!

Slayback Pharma in Hyderabad by Studio Mohenjodaro ArchitectureLive!

Slayback Pharma announces USD 20 million expansion in Hyderabad - Telangana Today

Slayback Pharma announces USD 20 million expansion in Hyderabad Telangana Today

Slayback Pharma appoints Dr Sumitra Pillai as Head of R&D - Healthcare Radius

Slayback Pharma appoints Dr Sumitra Pillai as Head of R&D Healthcare Radius

Everstone to invest $50 million in KKR-backed Slayback Pharma - The Economic Times

Everstone to invest $50 million in KKR-backed Slayback Pharma The Economic Times

Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL - PR Newswire

Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL PR Newswire

Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla® - PR Newswire

Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla® PR Newswire

Slayback Pharma announces approval of Icatibant Injection 30 mg/3 ml (10 mg/ ml), generic equivalent of Firazyr®. - PR Newswire

Slayback Pharma announces approval of Icatibant Injection 30 mg/3 ml (10 mg/ ml), generic equivalent of Firazyr®. PR Newswire

Top Slayback Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant